Catalent Inc (CTLT) Stock Price, Quote, News and Overview
NYSE:CTLT - New York Stock Exchange, Inc. - US1488061029 - Common Stock - Currency: USD
CTLT Quote, Performance and Key Statistics
63.48
0 (0%)
The current stock price of CTLT is 63.48 USD. In the past month the price increased by 8%. In the past year, price increased by 44.01%.
CTLT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About CTLT
Company Profile
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company is headquartered in Somerset, New Jersey and currently employs 16,900 full-time employees. The company went IPO on 2014-07-31. The Company’s Biologics segment provides formulation, development, and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. The company also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for oral solid doses forms, softgels, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms. The company also provides formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.
Company Info
Catalent Inc
14 Schoolhouse Rd
Somerset NEW JERSEY 08873 US
CEO: John R. Chiminski
Employees: 16900
Company Website: https://www.catalent.com/
Investor Relations: https://investor.catalent.com
Phone: 17325376200
Catalent Inc / CTLT FAQ
What is the stock price of Catalent Inc today?
The current stock price of CTLT is 63.48 USD.
What is the ticker symbol for Catalent Inc stock?
The exchange symbol of Catalent Inc is CTLT and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is CTLT stock listed?
CTLT stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for Catalent Inc stock?
14 analysts have analysed CTLT and the average price target is 64.77 USD. This implies a price increase of 2.03% is expected in the next year compared to the current price of 63.48. Check the Catalent Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Catalent Inc worth?
Catalent Inc (CTLT) has a market capitalization of 11.52B USD. This makes CTLT a Large Cap stock.
How many employees does Catalent Inc have?
Catalent Inc (CTLT) currently has 16900 employees.
What are the support and resistance levels for Catalent Inc (CTLT) stock?
Catalent Inc (CTLT) has a support level at 61.63 and a resistance level at 63.49. Check the full technical report for a detailed analysis of CTLT support and resistance levels.
Is Catalent Inc (CTLT) expected to grow?
The Revenue of Catalent Inc (CTLT) is expected to grow by 8.33% in the next year. Check the estimates tab for more information on the CTLT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Catalent Inc (CTLT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CTLT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CTLT, evaluating the profitability, health, valuation and growth aspects
- Catalent Inc (CTLT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Catalent Inc (CTLT) Sales and EPS estimates to see what analysts future expectations are.
- Catalent Inc (CTLT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Catalent Inc (CTLT) Insider and Institutional Ownership to learn about the owners and their transactions.
- Catalent Inc (CTLT) Stock Chart to make your own analysis
- Catalent Inc (CTLT) Latest news and press-releases to stay up to date.
Does Catalent Inc (CTLT) stock pay dividends?
CTLT does not pay a dividend.
When does Catalent Inc (CTLT) report earnings?
Catalent Inc (CTLT) will report earnings on 2025-02-07, after the market close.
What is the Price/Earnings (PE) ratio of Catalent Inc (CTLT)?
The PE ratio for Catalent Inc (CTLT) is 288.55. This is based on the reported non-GAAP earnings per share of 0.22 and the current share price of 63.48 USD. Check the full fundamental report for a full analysis of the valuation metrics for CTLT.
CTLT Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CTLT. When comparing the yearly performance of all stocks, CTLT is one of the better performing stocks in the market, outperforming 86.78% of all stocks.
CTLT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CTLT. CTLT has a bad profitability rating. Also its financial health evaluation is rather negative.
CTLT Financial Highlights
Over the last trailing twelve months CTLT reported a non-GAAP Earnings per Share(EPS) of 0.22. The EPS decreased by -61.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.25% | ||
| ROE | -11.66% | ||
| Debt/Equity | 1.38 |
CTLT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 53% to CTLT. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 350.55% and a revenue growth 8.33% for CTLT